

Date: March 23, 2016

To: The Manager – Listing

- a) BSE Limited
- b) National Stock Exchange of India Limited

Dear Sir(s)

Sub: Press Release dated March 23, 2016

Please find attached a copy of the press release dated March 23, 2016 being issued by AstraZeneca Pharma India Limited ("the Company"), in connection with Distribution Services Agreement entered into by the Company with Sun Pharma Laboratories Limited, for innovative Type 2 diabetes medicine, dapagliflozin.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited



Anantha Murthy N

Legal Counsel & Company Secretary

Enclosure: As above.

Sun Pharma and AstraZeneca India enter partnership in Type 2 diabetes

Sun Pharma signs distribution agreement for AstraZeneca India's innovative Type 2 diabetes medicine, dapagliflozin

*SGLT2 inhibitor dapagliflozin is AstraZeneca India's leading diabetes medicine**

Mumbai & Bangalore, India: March 23, 2016 - AstraZeneca Pharma India Limited (AstraZeneca India) (BSE : 506820, NSE : ASTRAZEN) and Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharmaceutical Industries Ltd and includes its subsidiaries or associate companies) today announced a partnership for the distribution of dapagliflozin, an innovative Type 2 diabetes medicine, in India. Dapagliflozin is AstraZeneca India's leading diabetes medicine.

Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name "Oxra®". AstraZeneca India markets dapagliflozin under the brand name Forxiga® and under the terms of the agreement, both companies will promote, market & distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights to dapagliflozin.

Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name "Oxramet™", following regulatory approval. AstraZeneca India is currently seeking approval from the Drug Controller General of India for the combination of dapagliflozin with metformin

Commenting on the agreement with AstraZeneca India, Mr Abhay Gandhi, CEO – India Business, Sun Pharma said, "This agreement for dapagliflozin further strengthens our partnership with AstraZeneca India. The addition of this innovative Type 2 diabetes treatment bolsters our diabetes portfolio. We believe the extended portfolio will further enhance our service capabilities to offer customers & patients innovative medicines at affordable prices. Sun Pharma enjoys a strong relationship with the physician community, especially diabetologists, endocrinologists and consulting physicians treating patients with diabetes across India. Through this partnership with AstraZeneca, access to dapagliflozin will be enhanced for doctors & Type 2 diabetes patients in India."

Commenting on the agreement, Sanjay Murdeshwar, Managing Director, AstraZeneca India stated, "AstraZeneca is committed to addressing unmet need in the treatment of Type 2 diabetes by offering treatment options to physicians that meet the needs of individual patients. Dapagliflozin represents a significant advancement in the treatment of Type 2 diabetes and this agreement supports our strategy of working with a local partner to maximize the value from our innovative

medicines in a key emerging market. It ensures a greater number of patients will have access to this important treatment option.”

Diabetes (all types) is estimated to affect approximately 69.2 million people in India and more than 415 million people worldwide. By 2040, this will rise to 642 million and Type 2 is the most common form of diabetes.**

The size of the overall Indian diabetes treatment market is more than Rs. 8400 crore* (this includes Type1 and Type 2), growing at approximately 21 percent* year-on-year and highly fragmented with approximately 50 active players. However, the top 5 players (which includes Sun Pharma) cumulatively account for 50% of this market. Sun Pharma’s current diabetes portfolio comprises of over 40 specialty products with a market share of more than 8 percent. It has the potential to significantly expand patient access to dapagliflozin and the combination of dapagliflozin with metformin treatment in India.

AstraZeneca India has a broad non-insulin portfolio addressing Type 2 diabetes and offers medicines in all the three novel and fast growing classes of Type 2 diabetes treatments: Dipeptidyl Peptidase-4 (DPP-4) inhibitors, SGLT2 inhibitor and glucagon-like peptide 1 (GLP-1) agonists in India.

* Source - IMS Feb 2016 MAT data

** International Diabetes Federation, Diabetes Atlas 7th Edition, 2015

ABOUT DAPAGLIFLOZIN

Dapagliflozin tablets are approved as a once-daily oral medication in adult patients with Type 2 diabetes mellitus to improve glycaemic control:

- As a monotherapy, when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; or
- In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.

The medicine is not indicated as a weight loss product or for the management of obesity or high blood pressure, and has only been studied for the treatment of Type 2 diabetes.

ABOUT SUN PHARMA: (CIN - L24230GJ1993PLC019050)

Sun Pharma is world's fifth largest specialty generic and India's top pharmaceutical company. With a vertically integrated business, economies of scale, an extremely skilled team enabling delivery of quality products at affordable prices and trusted by customers and patients in over 150 countries globally. Sun Pharma's global presence is supported by 49 manufacturing facilities spread across 6 continents, R&D centres worldwide and a multi-cultural workforce representing more than 50 nationalities. The consolidated revenues for 12 months ending March 31, 2015 was approximately US\$ 4.5 billion, of which US contributed US\$ 2.2 billion. In India, Sun Pharma enjoys leadership across 12 different classes of doctors with 30 brands featuring amongst top 300 pharmaceutical brands. Its footprint across emerging markets covers more than 100 markets and six markets in Western Europe. The Global Consumer Healthcare business is ranked amongst Top 10 across 4 global markets and the



API business footprint is strengthened through 14 world class API manufacturing facilities world-over. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising about 2,000 scientists and investments of over 7% of annual revenues.

For further information please visit www.sunpharma.com

Follow us on Twitter @SunPharma_Live

ABOUT ASTRAZENECA

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit www.astrazeneca.com

ABOUT ASTRAZENECA PHARMA INDIA LIMITED

AstraZeneca India was established in 1979 and is headquartered at Bengaluru, Karnataka. It is present in five crucial areas of healthcare - Cardiovascular, Diabetes, Oncology, Respiratory & Inflammation and Infection. AstraZeneca India has a workforce of over 1200 employees across the country that is committed to deliver great medicines to patients through innovative science and global excellence in development and commercialization. For more information please visit: www.astrazeneca.com/india

For Further Details Please Contact

Media Contact:

Sun Pharma

Frederick Castro

+91 9920665176

frederick.castro@sunpharma.com

AstraZeneca India

Varsha Das

+91 9741752900

Varsha.das1@astrazeneca.com

Investor Relations Contact

Sun Pharma

Nimish Desai

+91 9820330182

Nimish.desai@sunpharma.com